RocketVax

23/09/2022

RocketVax AG Announces New Milestones in the Development of Second-Generation COVID-19 Vaccines

Since the SARS-CoV-2 virus is here to stay and will continue to mutate, research and development of effective vaccines must continue as a high priority. Prof. Volker Thiel’s research group at the Institute of Virology and Immunology and the University of Bern is developing vaccines with an attenua...

02/08/2022

Swiss Rockets AG completes its leadership team by hiring Dr. Milan Crnogorac as Chief Technology Officer as of 1 August 2022.

10/06/2022

RocketVax's live-attenuated SARS-CoV-2 vaccine, RVX-sCPD9, exhibits superior efficacy compared to the existing mRNA and viral vector vaccines in animal models. The data shows that RVX-sCPD9 has critical advantages over available COVID-19 vaccines. It elicits robust immunity following single-dose vac...

17/04/2022

We wish you a very happy Easter! 🍀🍀🍀

07/04/2022

The theme for this year’s World Health Day is “Our Planet, Our Health". Amid the ongoing pandemic and pollution growing on the planet, diseases like cancer, asthma, and heart diseases are increasing rapidly. World Health Organization aims to focus global attention on the urgent actions needed to “keep humans and the planet healthy.”

08/03/2022

Our world would mean nothing without women. Their courage that exists in perfect harmony with amazing tenderness saves our world every day. Happy Women's Day! 🌷

22/12/2021

Dear friends,
The end of the year is a time of year for remembrance. We take stock of where we came from and have a moment to think about where we are going, as we pursue the future with hope. May your new year be all that you hope for, and may it be sprinkled with love and friendship. Happy Holidays! 🎄✨🍀

18/11/2021

Swiss Rockets AG announces today the appointment of Albert Muntane Casanova as Chief Financial Officers of Swiss Rockets Group. Mr. Albert Muntane Casanova (47) started as the Chief Financial Officer for all the Swiss Rockets group companies. He is responsible for the finance, strategy, and investme...

12/11/2021

Dr. Vladimir Cmiljanovic, CEO and founder of Swiss Rockets AG and RocketVax AG, has been named as the recipient of the 2021 Nikola Tesla Award for his accomplishments in the field of science.

Nikola Tesla Award is a prestigious, national award given by the Government of the Republic of Serbia and the Ministry of Foreign Affairs. The laureates of this award are prominent individuals of Serbian origin who have contributed to the promotion of Serbia and strengthening of ties between the motherland and Serbs in the region and the diaspora.

Dr. Vladimir Cmiljanovic has been named as the recipient of the Nikola Tesla Award for advocating the achievements of Serbian scientists in the world through his scientific attainments in the field of oncology, as well as for leading the team of experts in the development of the second generation of SARS-CoV-2 vaccine.
Congratulations! 👏👏👏

30/09/2021

Dr. Vladimir Cmiljanovic, CEO of RocketVax, spoke to Serbian Broadcasting Corporation about the development of a second-generation SARS-CoV-2 vaccine, RVX-13.
To see the full interview, watch the video below. 👇

05/07/2021

Die Basler Regierung mischt bei der Entwicklung eines weiteren Corona-Impfstoffs mit. Sie bewilligt eine Million Franken Finanzhilfe aus dem Standortförderfonds.

17/06/2021

Basel government approves one million for research to develop novel vaccine against SARS-CoV-2 coronavirus.
Basel University Hospital, the University of Basel, and the Swiss Tropical and Public Health Institute have agreed to collaborate with the company RocketVax and jointly advance research to develop a novel vaccine against the SARS-CoV-2 coronavirus.
Click on the link below and read the full article. ⬇️

Basel University Hospital, the University of Basel and the Swiss Tropical and Public Health Institute have agreed to collaborate with the company RocketVax and jointly advance research to develop a novel vaccine against the SARS-CoV-2 coronavirus. The University Hospital Basel (USB), the University....